# Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

Review · Siwei Wang, Chao Gao, Yi-Min Zheng, Yi Li, Jia‐Cheng Lu, Xiaoyong Huang, Jiabin Cai, Pengfei Zhang, Yuehong Cui, Ai‐Wu Ke

- Archive id: doi:10.1186/s12943-022-01518-8
- Published: 2022-02-21
- Venue: Molecular Cancer
- DOI: https://doi.org/10.1186/s12943-022-01518-8
- PMID: 35189910
- Citations: 478
- Source URL: https://doi.org/10.1186/s12943-022-01518-8
- PDF: https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/s12943-022-01518-8
- Provenance: openalex

## Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) system provides adaptive immunity against plasmids and phages in prokaryotes. This system inspires the development of a powerful genome engineering tool, the CRISPR/CRISPR-associated nuclease 9 (CRISPR/Cas9) genome editing system. Due to its high efficiency and precision, the CRISPR/Cas9 technique has been employed to explore the functions of cancer-related genes, establish tumor-bearing animal models and probe drug targets, vastly increasing our understanding of cancer genomics. Here, we review current status of CRISPR/Cas9 gene editing technology in oncological research. We first explain the basic principles of CRISPR/Cas9 gene editing and introduce several new CRISPR-based gene editing modes. We next detail the rapid progress of CRISPR screening in revealing tumorigenesis, metastasis, and drug resistance mechanisms. In addition, we introduce CRISPR/Cas9 system delivery vectors and finally demonstrate the potential of CRISPR/Cas9 engineering to enhance the effect of adoptive T cell therapy (ACT) and reduce adverse reactions.

_Abstract reproduced under CC-BY (publisher license, via OpenAlex)._

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.